Triple Antiemetic Regimen for Chemoradiotherapy in Cervical Cancer or Nasopharyngeal Cancer
Status:
Recruiting
Trial end date:
2024-09-30
Target enrollment:
Participant gender:
Summary
The study is to evaluate the antiemetic effect of adding fosaprepitant to biplet regimen of
tropisetron and dexamethasone for patients with cervical cancer or nasopharyngeal cancer
treated with radiotherapy and concomitant weekly cisplatin chemotherapy in a south Chinese
cohort.